14 completed, 2 active not recruiting. 16 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 14, Active not recruiting 2 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow LOXO-292: new trials by email Literature Review of LOXO-292 trials Research Report on LOXO-292
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants Rosuvastatin, Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 28 | 2023-07-27 | 2025-09-16 |
| A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 46 | 2022-04-19 | 2025-03-21 |
| A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 42 | 2021-12-03 | 2025-03-17 |
| A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 224 | 2021-10-29 | 2025-03-17 |
| Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants Selpercatinib, Ranitidine, Omeprazole - Healthy | Phase 1 | Completed | Eli Lilly and Company | 20 | 2019-07-08 | 2024-10-30 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants Selpercatinib, Moxifloxacin, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 32 | 2019-04-16 | 2025-09-18 |
| A Study of Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 18 | 2019-02-12 | 2025-05-18 |
| A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants Repaglinide, Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 16 | 2019-01-29 | 2025-12-11 |
| A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function Selpercatinib - Healthy, Renal Insufficiency | Phase 1 | Completed | Eli Lilly and Company | 37 | 2018-12-19 | 2025-09-18 |
| A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants Selpercatinib - Healthy, Hepatic Impairment | Phase 1 | Completed | Eli Lilly and Company | 36 | 2018-12-10 | 2025-04-13 |
| A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants [14C]-Selpercatinib, Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 12 | 2018-08-01 | 2025-04-23 |
| A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants Midazolam, Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 16 | 2018-07-12 | 2025-10-20 |
| A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants Selpercatinib, Omeprazole - Healthy | Phase 1 | Completed | Eli Lilly and Company | 20 | 2018-05-31 | 2025-09-19 |
| A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants Selpercatinib, Itraconazole, Rifampin - Healthy | Phase 1 | Completed | Eli Lilly and Company | 24 | 2018-05-11 | 2025-09-19 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
Breast Neoplasms (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Medullary (2) · Carcinoma, Non-Small-Cell Lung (2) · Central Nervous System Neoplasms (2) · Colonic Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Head and Neck Neoplasms (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2)
Eli Lilly and Company (13) · Loxo Oncology, Inc. (3)
United States (15) · Australia (2) · Canada (2) · Denmark (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Singapore (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Hong Kong (1) · Israel (1) · Switzerland (1)
PMID 32846060, PMID 32846061, PMID 34088726, PMID 35930972, PMID 36108661, PMID 36122315, PMID 36657661, PMID 37265412, PMID 37934000, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39983053, PMID 42874021
2017 (1), 2019 (1), 2023 (1)